Skip to content

EFFICACY OF SITZ BATH IN THE MANAGEMENT OF ABNORMAL VAGINAL DISCHARGE

EFFICACY OF ABZAN (SITZ BATH) IN THE MANAGEMENT OF ABNORMAL VAGINAL DISCHARGE : AN OPEN LABELLED INTERVENTIONAL CLINICAL TRIAL - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/091753
Enrollment
36
Registered
2025-07-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N898- Other specified noninflammatory disorders of vagina Health Condition 2: N898- Other specified noninflammatory disorders of vagina

Interventions

Intervention1: Abzan(Sitz bath): Patients will be advised to take a Abzan (sitz bath) with Polyherbal decoction (joshanda ) daily for 14 days. Patients who are going to take Abzan (sitz bath) will hav

Sponsors

State Unani Medical College Himmatganj Prayagraj
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Married women between 18 to 50 years of age with mild to moderate abnormal vaginal discharge. 2. Women presenting with abnormal vaginal discharge and/or associated with low backache, burning micturition, lower abdominal pain, dysuria, dyspareunia, vulvar itching, and irritation. 3. Patient who will give consent and able to do follow up.

Exclusion criteria

Exclusion criteria: 1.Pregnant, lactating, and unmarried women. 2. Patient suffering from severe systemic illness. 3. Patients with abnormal uterine bleeding or vaginal bleeding, ulceration, unhealthy cervix, genital prolapse or genital malignancy. 4.Concomitant skin disease at the application site like herpetic vesicles, genital psoriasis, tinea cruris contact dermatitis etc. 5. Patient who have received either CAM therapy or antibiotics, antifungals and antiprotozoals or use of vaginal douches in last 2 weeks. 6. Patients with Syphilis, Gonorrhoea, HIV. 7. H/O oral contraceptive pills use within 1 week and IUCD insertion within 3 months of enrolment.

Design outcomes

Primary

MeasureTime frame
improvement in abnormal vaginal discharge and or any associated symptoms assessed by VAS Improvement in the quality of life by (SF 12)Timepoint: 7TH AND 14TH DAY

Secondary

MeasureTime frame
Vaginal pH Whiff test Vaginal wet mountTimepoint: 7th, 14th day

Countries

India

Contacts

Public ContactKhushnuma Parveen

State Takmeel ut tib

drjamalakhtar@yahoo.com8052142175

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026